A study conducted by doctors at Mumbai's Tata Memorial Hospital, which claimed that tablets made from papaya leaf extract could help raise platelet counts in cancer patients undergoing chemotherapy, has run into serious trouble over how its data was handled. Within a short time of publication, questions began piling up over the way patient results were analysed, and the international medical journal that carried the paper has now opened its own review and attached a caution notice to the paper.
What the study actually claimed
Chemotherapy is a core part of cancer treatment, but it frequently causes a sharp drop in patients' platelet counts. When platelets fall too low, blood clotting is affected, and doctors are often forced to either reduce chemotherapy doses or delay the treatment schedule altogether. The Tata Memorial team enrolled chemotherapy patients whose platelet counts were falling and tested tablets made from papaya leaf extract on them. The researchers claimed the tablets helped raise platelet counts in these patients. They also said that if future studies replicate the same results, the extract could turn into a low-cost and easily accessible option for patients, since papaya leaf extract is considered far cheaper than many existing medicines.
Why a Kochi liver specialist raised the alarm
After the study drew attention, Dr. Cyriac Abby Philips, a liver specialist based in Kochi, reviewed the underlying data closely. He alleged that the way patient data was analysed made the results look considerably better than the actual situation. According to Dr. Philips, some patients who did not show the expected improvement were excluded from the final calculations, while patients whose condition did improve were kept in the data set. He argued that this kind of selective counting made the success rate appear far higher and more impressive than it likely was in reality.
Questions over the placebo group and the goalposts
The criticism was not limited to the group that received the actual tablets. It also emerged that some patients in the placebo group, those given an inactive tablet for comparison, whose condition had improved were similarly excluded from the final analysis. Critics argue that if data from both groups, the treatment arm and the placebo arm, is trimmed this way, it becomes difficult to trust the study's overall conclusions. On top of that, clinical trials are supposed to fix in advance exactly which day or measure will count as the primary endpoint, the single most important result the trial is designed to test. Critics allege that in this study, the timing of that primary assessment was changed partway through, even though standard scientific practice requires such a decision to be locked in before the trial even begins. That allegation has fuelled a wider debate over the study's methodology.
How the Tata Memorial researchers have responded
Dr. Vikas Ostwal, the lead researcher on the study, said the medical journal had sent a set of questions and that his team was responding to every point raised. He described this kind of scrutiny after publication as a normal part of the scientific process, not something unusual. Dr. Ostwal added that, in his own experience, patients who were given the tablets showed rising platelet counts within a matter of days. At the same time, he acknowledged that it is important to wait for the journal's review to conclude before drawing any final conclusions.
The funding question
Another thread of the controversy concerns who paid for the research. The study received financial support from pharmaceutical companies, and the tablets used in the trial were also supplied by a drug company. Notably, one of the companies that funded the research already sells a similar product in the market, meaning it stands to benefit directly if the study's findings are validated. The research team, however, maintains that its scientific process remained independent throughout the study and that it was not aware of this commercial angle at the time.
What action has the journal taken
The international medical journal that published the study has now attached a public notice to the paper. It states that the study's data is being re-examined in detail and that, until the review is complete, readers should treat the findings with caution. Within the scientific community, this kind of notice is seen as a routine part of maintaining transparency and is meant to preserve trust in published research going forward.
What this means for ordinary patients and families
None of this means that papaya leaf extract is either fully effective or completely useless. What it means is that the specific findings of this particular study are being scrutinised once again. Until that scientific review is complete, and until independent studies repeatedly show similar results, it would be premature to treat this claim as settled fact. For anyone dealing with cancer treatment or platelet-related problems, the safest approach remains relying on a doctor's advice rather than acting on this claim alone.
